Basket | Login


Special Symposium SS2: PharmaCog: Bringing new hope to patients with Alzheimer’s disease

Detailed Programme and abstracts

Saturday, 2 October 2010: 13.00-14.00 (Blue Room)

Elaine A Irving, PharmaCog Co-Coordinator, GlaxoSmithKline R&D Ltd., UK

Esther Schenker, Institut de Recherche Servier, France

David Bartres-Faz, 3Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Faculty of Medicine, University of Barcelona

Alexandra Auffret, PharmaCog Project Manager, University of Marseille

Despite the increase in translational medicine activities in recent years, there is not only a lack of agreement regarding the predictive value of behavioural, neuroimaging, and electrophysiological markers to be used for Alzheimer’s disease drug discovery, the number of successful new drugs reaching patients is still very low. The launch of the five year €20M PharmaCog project funded under the Innovative Medicine Initiative marks the beginning of the most ambitious European project aimed at improving the success rate in AD drug discovery.

This ambitious project brings together leading scientists from 29 organisations comprising public institutions, corporate partners as well as the patients’ association Alzheimer Europe. PharmaCog will also work closely with the European Medicines Agency (EMA), as an associated partner of this project, to share project progress and discuss the implications for drug development in Europe. This is a truly unique opportunity bringing together world leaders with a diverse range of expertise and experiences to work together to improve our ability to assess the potential clinical value of a new drug candidate. It is anticipated that such a concerted effort will minimise the risk of progression of unsuitable compounds and accelerate the development of promising new medicines for AD.

In this session you will hear more about the scientific approach being taken by PharmaCog investigators, how this initiative differs from other ongoing research activities and how this will provide direct benefit Alzheimer patients in Europe.






Last Updated: Wednesday 03 November 2010